SDSUV Result 2017

Vital Therapies trades as part of the healthcare sector and is part of the biotechnology industry. The company CEO is Duane D. Nash. Vital Therapies Inc is a biotherapeutic company. The Company is engaged in developing a cell-based therapy targeting treatment acute forms of liver failure. Its product includes the ELAD System an extracorporeal bio-artificial liver support system.



Previous Intraday Performance:

The VTL shares had a previous change of 7.78% which opened at 1.02 and closed at 0.83. It moved to an intraday high of 1.17 and a low of 0.78.

PR Newswire:  Immunic Therapeutics and Vital Therapies Complete Transaction Creating Nasdaq-Listed Company Targeting Chronic Inflammatory and Autoimmune Diseases

Historical Performance:

Over the last five trading days, VTL shares returned 13.93% and in the past 30 trading days it returned 249.92%. Over three months, it changed 259.31%. In one year it has changed -85.57% and within that year its 52 week high was 9.75 and its 52 week low was 0.15. VTL stock is 449.67% above its 52 week low.

Our calculations result in a 200 day moving average of 2.39 and a 50 day moving average of 0.27. Right now, VTL stock is trading -65.33% below its 200 day moving average and may not be a great opportunity to buy as it may continue to trend down.

PR Newswire:  Immunic Therapeutics and Vital Therapies Complete Transaction Creating Nasdaq-Listed Company Targeting Chronic Inflammatory and Autoimmune Diseases

Liquidity:

The company has a market cap of $35.2m with 42.4m shares outstanding and a float of 42.0m shares. Trading volume was 85,776,727 shares and has experienced an average volume of 14,861,616 shares. Our calculation, using the current average volume and close price, leads me to believe that the liquidity is bad, highly speculative and an investor may want to avoid this stock.

Earnings:

The last annual reported EPS for Vital Therapies was -0.98 which ended on 31st of December 2018.

20 0.00 (estimated) 20 0.00 20 0.00 20 0.00 20 0.00

The long-term trend of the EPS is an important number as it indicates the present value of Vital Therapies.

Indicators Also to Watch:

Based on the latest filings, there is 0.80% of insider ownership and 30.80% of institutional ownership.

The beta was calculated to be 4.45.



SeekingAlpha:  Varonis Systems’ (VRNS) CEO Yaki Faitelson on Q1 2019 Results – Earnings Call Transcript

Fundamental Numbers:

Based on last reported financials, the company’s return on assets is -127.26% and price-to-book is 3.89.

Company Score Card:

Results are out of six:
 0  : Growth Expectations Result
 4  : Financial Safety Result
 0  : Past Performance Result
 0  : Valuation Result
 0  : Dividend Safety Result
 1  : Overall Result

Related Tags: , , ,

Jake McWilliams
I am an independent trader, analyst and algorithmic trading expert, having worked both for the sell side (brokerage) and the buy side (fund administration). I have been trading professionally for about 20 years. I trade stocks and forex and I play both long and short positions in underlying asset or through options. I have experience with discretionary and fully automated systems (Metatrader and Quantshare).

LEAVE A REPLY

Please enter your comment!
Please enter your name here